Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution

被引:42
作者
Sadagopan, N
Cohen, L
Roberts, B
Collard, W
Omer, C
机构
[1] Pfizer Global Res & Div, Ann Arbor Labs, Pharmacokinet Dynam & Metab Dept, Ann Arbor, MI 48105 USA
[2] Pfizer Global Res & Div, Ann Arbor Labs, Ann Arbor, MI 48105 USA
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 759卷 / 02期
关键词
cyclophosphamide; hydroxycyclophosphamide;
D O I
10.1016/S0378-4347(01)00243-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cyclophosphamide (CP) and its metabolite, hydroxycyclophosphamide (OH-CP) have been quantitated in mouse plasma and tissue by derivatization combined with liquid chromatography-tandem mass spectrometry (LC-MS-MS). The derivatization was conducted immediately upon sample collection, to trap the OH-CP metabolite intermediate prior to further conversion to phosphoramide mustard or other reaction products. This simple and straightforward derivatization procedure, combined with sample extraction via protein precipitation, allowed quantitation of CP and the oxime derivative of OH-CP in plasma for concentrations ranging from approximately 12.5-3333 ng/ml, and in spleen tissue for concentrations of 1250-50 000 ng/g. The short cycle time (2.5 min) of the LC-MS-MS method allowed high throughput analysis with minimal matrix interference. Mouse plasma levels were quantitated for doses of 40, 65 and 120 mg/kg; spleen concentrations were determined for mice dosed at 120 mg/kg. The CP acid oxime plasma levels correlated well with dose amounts. The CP levels in the spleen and plasma were similar while the oxime levels in the spleen were significantly lower than the plasma. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 13 条
[1]   Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry [J].
Baumann, F ;
Lorenz, C ;
Jaehde, U ;
Preiss, R .
JOURNAL OF CHROMATOGRAPHY B, 1999, 729 (1-2) :297-305
[2]   ANALYSIS OF 4-HYDROXYCYCLOPHOSPHAMIDE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY IN PLASMA [J].
HONG, PS ;
CHAN, KK .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 495 :131-138
[3]  
KWON CH, 1987, CANCER RES, V47, P1505
[4]  
Ludeman SM, 1999, CURR PHARM DESIGN, V5, P627
[5]  
MARLETMARTINO M, 1999, CURR PHARM DESIGN, V5, P561
[6]   CLINICAL PHARMACOKINETICS OF CYCLOPHOSPHAMIDE [J].
MOORE, MJ .
CLINICAL PHARMACOKINETICS, 1991, 20 (03) :194-208
[7]   Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients [J].
Slattery, JT ;
Kalhorn, TF ;
McDonald, GB ;
Lambert, K ;
Buckner, CD ;
Bensinger, WI ;
Anasetti, C ;
Appelbaum, FR .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1484-1494
[8]  
Sottani C, 1998, RAPID COMMUN MASS SP, V12, P1063, DOI 10.1002/(SICI)1097-0231(19980831)12:16<1063::AID-RCM287>3.3.CO
[9]  
2-B
[10]   ANALYSIS OF 4-HYDROXYCYCLOPHOSPHAMIDE IN HUMAN BLOOD [J].
WRIGHT, JE ;
TRETYAKOV, O ;
AYASH, LJ ;
ELIAS, A ;
ROSOWSKY, A ;
FREI, E .
ANALYTICAL BIOCHEMISTRY, 1995, 224 (01) :154-158